Review of future follow-up clinical progress and product development strategy
[by Ji, Yong Jun] 카지노 룰렛 사이트 Pharmaceutical announced on March 12 that the phase 1 clinical trial results of 'DW1022’ (development code), a patch candidate utilizing 'semaglutide,' the active ingredient of the global blockbuster obesity treatment 'Wegovy,' demonstrated excellent tolerability and safety. DW1022 is a microneedle patch-type obesity treatment candidate co-developed by 카지노 룰렛 사이트 Pharmaceutical and Raphas.
카지노 룰렛 사이트 Pharmaceutical received domestic phase 1 clinical trial approval for DW1022 in March 2024 and has recently completed the trial. The results confirmed biological equivalence between DW1022 and the control group, Wegovy, with no differences in safety profile observed. 카지노 룰렛 사이트 Pharmaceutical stated that it concluded that repeated administration of DW1022 would achieve a maintenance dose equivalent to that of Wegovy.
"Based on the results of this clinical trial, we will evaluate the direction for subsequent clinical trials and further product development," a 카지노 룰렛 사이트 Pharmaceutical official said.